Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers 2021

Steve Soper's Biography



Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas, Adjunct Professor, Ulsan National Institute of Science & Technology

Prof. Soper (since 2016) is a Foundation Distinguished Professor in Chemistry and Mechanical Engineering at the University of Kansas. At KUMC, Prof. Soper holds an adjunct appointment in the Cancer Biology Department and is a member of the KU Cancer Center. He also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor.
As a result of his efforts, Prof. Soper has secured extramural funding totaling >$125M, has published over 245 peer-reviewed manuscripts (h index = 70; >17,000 citations); 31 book chapters and 71 peer-reviewed conference proceeding papers, and is the author of 12 patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of liquid biopsy markers. Soper recently founded a second company, Sunflower Genomics, which is seeking to market a new DNA/RNA single-molecule sequencing platform. His list of awards includes Ralph Adams Award in Bioanalytical Chemistry, Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award for Microchemistry, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer in the state of Louisiana in 2001. Finally, Prof. Soper has granted 50 PhDs and 7 MS degrees to students under his mentorship. He currently heads a group of 15 researchers. His major discoveries include: (1) Technology for the detection of liquid biopsy markers that can manage a variety of diseases using a simple blood test (test has been demonstrated in multiple myeloma, pediatric acute lymphoblastic leukemia, acute myeloid leukemia, pancreatic, breast, colorectal, prostate, and ovarian cancers); (2) new hardware and assay for the point-of-care diagnosis of acute ischemic stroke; (3) single-molecule DNA and RNA sequencing nanotechnology; and (4) currently working on a home-test for COVID-19 infections (handheld instrument and the associated assay.

Steve Soper Image

Repurposing Microfluidic Tools for the Analysis of Liquid Biopsy Markers for COVID-19 Diagnostics

Friday, 26 February 2021 at 13:45

Add to Calendar ▼2021-02-26 13:45:002021-02-26 14:45:00Europe/LondonRepurposing Microfluidic Tools for the Analysis of Liquid Biopsy Markers for COVID-19 DiagnosticsCirculating Biomarkers 2021 in Virtual ConferenceVirtual ConferenceSELECTBIOenquiries@selectbiosciences.com

Extracellular vesicles (EVs), which are sub-micrometer sized particles produced from biological cells, can be isolated from liquid biopsy samples and used to manage a variety of diseases including the oncology-related diseases as well as others. However, disease-associated EVs must first be isolated in high purity to secure quality molecular data because even non-diseased cells produce EVs that can mask subtle disease-related molecular alterations. We have developed a plastic microfluidic chip, which is injection molded, consisting of 1.5M micropillars decorated with affinity agents to allow for selecting EVs from plasma. We have repurposed this chip to select SARS-CoV-2 virus particles (VPs) directly from saliva. In this presentation, we discuss an assay that can accept saliva samples and search for VPs (VP selection chip) and then, count the number of VPs selected using a label-free approach; nano-Coulter Counter chip (nCC). The VP selection chip affinity targeted SARS-CoV-2 VPs using an aptamer surface immobilized to pillars contained within the chip that were directed against the SARS-CoV-2 Spike protein. The VP selection chip allowed for affinity loading up to 1010 SARS-CoV-2 VPs. Following selection (VP recovery >40%) and subsequent release (~89% efficiency) from the VP selection chip using a photocleavable linker and a blue-light LED, the selected particles were counted using the nCC chip. For high throughput VP counting, 5 nCCs were placed in parallel and offered 100% detection efficiency for VPs travelling through a 200 nm in-plane pore. The entire assay could be completed in ~20 min with full process automation. In addition, the selected particles were available for analysis of their RNA content using RT-qPCR. For a 20 sample set, RT-qPCR identified 4 samples of infected individuals and our assay was successful in identifying all 4 of those samples. The chips and controlling electronics could be packaged into a handheld instrument to allow for point-of-care testing or even at-home testing.


Add to Calendar ▼2021-02-25 00:00:002021-02-26 00:00:00Europe/LondonCirculating Biomarkers 2021Circulating Biomarkers 2021 in Virtual ConferenceVirtual ConferenceSELECTBIOenquiries@selectbiosciences.com